CERO THERAPEUTICS HOLDINGS, INC. Restricted Cash and Cash Equivalents
CERO THERAPEUTICS HOLDINGS, INC. (CERO) had Restricted Cash and Cash Equivalents of $3.30 million as of 2024-12-31, per its 10-K filed 2025-04-15.
Financial Statements › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCashAndCashEquivalents · last filed 2025-04-15
- 2024-12-31: Restricted Cash and Cash Equivalents $3.30M.
- 2024-09-30: Restricted Cash and Cash Equivalents $3.40M.
- 2024-06-30: Restricted Cash and Cash Equivalents $3.60M.
- 2023-12-31: Restricted Cash and Cash Equivalents $96.87K.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2024-12-31 | $3.30M 10-K · filed 2025-04-15 |
| 2024-09-30 | $3.40M 10-Q/A · filed 2024-11-20 |
| 2024-06-30 | $3.60M 10-Q · filed 2024-08-14 |
| 2023-12-31 | $96.87K 10-K · filed 2024-04-02 |
| 2022-12-31 | $42.14M 10-K · filed 2024-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |